Drozitumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | DR5 |
| Clinical data | |
| Identifiers | |
912628-39-8  | |
| None | |
| UNII |
SQ67484MA7  |
| Chemical data | |
| Formula | C6334H9792N1700O2000S42 |
| 143.1 kDa | |
| (what is this?) (verify) | |
Drozitumab is a human monoclonal antibody designed for the treatment of cancers.[1]
Drozitumab was developed by Genentech.
References
- ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab" (PDF). American Medical Association.